Lowell L. Hart

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

Mace L. Rothenberg, Amit M. Oza, Robert Bigelow et al. · Journal of Clinical Oncology · 2003 · 642 citations

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Howard S. Höchster, Lowell L. Hart, Ramesh K. Ramanathan et al. · Journal of Clinical Oncology · 2008 · 620 citations

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 554 citations

Pharmacological Study, Efficacy Data, Pharmacology +7

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Roy S. Herbst, Vincent O’Neill, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2007 · 396 citations · Full text